In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales.
Identifieur interne : 000322 ( Main/Exploration ); précédent : 000321; suivant : 000323In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales.
Auteurs : Patrick Schwarz [Allemagne] ; Petra V. Schwarz [Allemagne] ; Heike Felske-Zech [Allemagne] ; Eric Dannaoui [France]Source :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2019.
Descripteurs français
- KwdFr :
- Antifongiques (pharmacologie), Ciclosporine (pharmacologie), Immunosuppresseurs (pharmacologie), Mucorales (effets des médicaments et des substances chimiques), Mucormycose (microbiologie), Mucormycose (traitement médicamenteux), Nitriles (pharmacologie), Pyridines (pharmacologie), Sirolimus (pharmacologie), Tacrolimus (pharmacologie), Tests de sensibilité microbienne (MeSH), Triazoles (pharmacologie).
- MESH :
- effets des médicaments et des substances chimiques : Mucorales.
- microbiologie : Mucormycose.
- pharmacologie : Antifongiques, Ciclosporine, Immunosuppresseurs, Nitriles, Pyridines, Sirolimus, Tacrolimus, Triazoles.
- traitement médicamenteux : Mucormycose.
- Tests de sensibilité microbienne.
English descriptors
- KwdEn :
- Antifungal Agents (pharmacology), Cyclosporine (pharmacology), Immunosuppressive Agents (pharmacology), Microbial Sensitivity Tests (MeSH), Mucorales (drug effects), Mucormycosis (drug therapy), Mucormycosis (microbiology), Nitriles (pharmacology), Pyridines (pharmacology), Sirolimus (pharmacology), Tacrolimus (pharmacology), Triazoles (pharmacology).
- MESH :
- chemical , pharmacology : Antifungal Agents, Cyclosporine, Immunosuppressive Agents, Nitriles, Pyridines, Sirolimus, Tacrolimus, Triazoles.
- drug effects : Mucorales.
- drug therapy : Mucormycosis.
- microbiology : Mucormycosis.
- Microbial Sensitivity Tests.
Abstract
OBJECTIVES
To evaluate the in vitro interactions of isavuconazole with immune suppressors (tacrolimus, cyclosporin A or sirolimus) against 30 Mucorales isolates belonging to the most common species responsible for mucormycosis in humans (Rhizopus arrhizus, Rhizopus delemar, Rhizopus microsporus, Lichtheimia corymbifera, Lichtheimia ramosa, Mucor circinelloides and Rhizomucor pusillus).
METHODS
In vitro interaction was evaluated by a microdilution chequerboard technique.
RESULTS
Combination of isavuconazole with tacrolimus, cyclosporin A or sirolimus, was synergistic for 50%, 46% and 7% of the isolates, respectively. Antagonistic interaction was observed for 4% of the isolates for the combination with cyclosporin A (one R. arrhizus isolate) and for 32% of the isolates for the combination with sirolimus (six R. arrhizus isolates and three R. pusillus isolates).
CONCLUSIONS
These in vitro data show that calcineurin inhibitors are more likely than inhibitors of the mTOR pathway to enhance the activity of isavuconazole against Mucorales. These in vitro results warrant further animal experiments.
DOI: 10.1093/jac/dkz102
PubMed: 30934052
Affiliations:
- Allemagne, France
- District de Giessen, Hesse (Land), Île-de-France
- Créteil, Marbourg, Paris
- Université Paris-Descartes
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales.</title><author><name sortKey="Schwarz, Patrick" sort="Schwarz, Patrick" uniqKey="Schwarz P" first="Patrick" last="Schwarz">Patrick Schwarz</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Schwarz, Petra V" sort="Schwarz, Petra V" uniqKey="Schwarz P" first="Petra V" last="Schwarz">Petra V. Schwarz</name><affiliation wicri:level="3"><nlm:affiliation>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Felske Zech, Heike" sort="Felske Zech, Heike" uniqKey="Felske Zech H" first="Heike" last="Felske-Zech">Heike Felske-Zech</name><affiliation wicri:level="1"><nlm:affiliation>Department of Legal Medicine, University Hospital Gießen, Gießen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Legal Medicine, University Hospital Gießen, Gießen</wicri:regionArea><wicri:noRegion>Gießen</wicri:noRegion><wicri:noRegion>Gießen</wicri:noRegion><wicri:noRegion>Gießen</wicri:noRegion></affiliation></author><author><name sortKey="Dannaoui, Eric" sort="Dannaoui, Eric" uniqKey="Dannaoui E" first="Eric" last="Dannaoui">Eric Dannaoui</name><affiliation wicri:level="4"><nlm:affiliation>Université Paris Descartes, Faculté de Médecine, AP-HP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris Descartes, Faculté de Médecine, AP-HP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Dynamyc Research Group (EA 7380), Paris Est Créteil University, Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dynamyc Research Group (EA 7380), Paris Est Créteil University, Créteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30934052</idno><idno type="pmid">30934052</idno><idno type="doi">10.1093/jac/dkz102</idno><idno type="wicri:Area/Main/Corpus">000309</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000309</idno><idno type="wicri:Area/Main/Curation">000309</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000309</idno><idno type="wicri:Area/Main/Exploration">000309</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales.</title><author><name sortKey="Schwarz, Patrick" sort="Schwarz, Patrick" uniqKey="Schwarz P" first="Patrick" last="Schwarz">Patrick Schwarz</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Schwarz, Petra V" sort="Schwarz, Petra V" uniqKey="Schwarz P" first="Petra V" last="Schwarz">Petra V. Schwarz</name><affiliation wicri:level="3"><nlm:affiliation>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Felske Zech, Heike" sort="Felske Zech, Heike" uniqKey="Felske Zech H" first="Heike" last="Felske-Zech">Heike Felske-Zech</name><affiliation wicri:level="1"><nlm:affiliation>Department of Legal Medicine, University Hospital Gießen, Gießen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Legal Medicine, University Hospital Gießen, Gießen</wicri:regionArea><wicri:noRegion>Gießen</wicri:noRegion><wicri:noRegion>Gießen</wicri:noRegion><wicri:noRegion>Gießen</wicri:noRegion></affiliation></author><author><name sortKey="Dannaoui, Eric" sort="Dannaoui, Eric" uniqKey="Dannaoui E" first="Eric" last="Dannaoui">Eric Dannaoui</name><affiliation wicri:level="4"><nlm:affiliation>Université Paris Descartes, Faculté de Médecine, AP-HP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris Descartes, Faculté de Médecine, AP-HP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Dynamyc Research Group (EA 7380), Paris Est Créteil University, Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dynamyc Research Group (EA 7380), Paris Est Créteil University, Créteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author></analytic><series><title level="j">The Journal of antimicrobial chemotherapy</title><idno type="eISSN">1460-2091</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antifungal Agents (pharmacology)</term><term>Cyclosporine (pharmacology)</term><term>Immunosuppressive Agents (pharmacology)</term><term>Microbial Sensitivity Tests (MeSH)</term><term>Mucorales (drug effects)</term><term>Mucormycosis (drug therapy)</term><term>Mucormycosis (microbiology)</term><term>Nitriles (pharmacology)</term><term>Pyridines (pharmacology)</term><term>Sirolimus (pharmacology)</term><term>Tacrolimus (pharmacology)</term><term>Triazoles (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antifongiques (pharmacologie)</term><term>Ciclosporine (pharmacologie)</term><term>Immunosuppresseurs (pharmacologie)</term><term>Mucorales (effets des médicaments et des substances chimiques)</term><term>Mucormycose (microbiologie)</term><term>Mucormycose (traitement médicamenteux)</term><term>Nitriles (pharmacologie)</term><term>Pyridines (pharmacologie)</term><term>Sirolimus (pharmacologie)</term><term>Tacrolimus (pharmacologie)</term><term>Tests de sensibilité microbienne (MeSH)</term><term>Triazoles (pharmacologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antifungal Agents</term><term>Cyclosporine</term><term>Immunosuppressive Agents</term><term>Nitriles</term><term>Pyridines</term><term>Sirolimus</term><term>Tacrolimus</term><term>Triazoles</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Mucorales</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Mucormycosis</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Mucorales</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Mucormycose</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Mucormycosis</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antifongiques</term><term>Ciclosporine</term><term>Immunosuppresseurs</term><term>Nitriles</term><term>Pyridines</term><term>Sirolimus</term><term>Tacrolimus</term><term>Triazoles</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mucormycose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Microbial Sensitivity Tests</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Tests de sensibilité microbienne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To evaluate the in vitro interactions of isavuconazole with immune suppressors (tacrolimus, cyclosporin A or sirolimus) against 30 Mucorales isolates belonging to the most common species responsible for mucormycosis in humans (Rhizopus arrhizus, Rhizopus delemar, Rhizopus microsporus, Lichtheimia corymbifera, Lichtheimia ramosa, Mucor circinelloides and Rhizomucor pusillus).</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>In vitro interaction was evaluated by a microdilution chequerboard technique.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Combination of isavuconazole with tacrolimus, cyclosporin A or sirolimus, was synergistic for 50%, 46% and 7% of the isolates, respectively. Antagonistic interaction was observed for 4% of the isolates for the combination with cyclosporin A (one R. arrhizus isolate) and for 32% of the isolates for the combination with sirolimus (six R. arrhizus isolates and three R. pusillus isolates).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>These in vitro data show that calcineurin inhibitors are more likely than inhibitors of the mTOR pathway to enhance the activity of isavuconazole against Mucorales. These in vitro results warrant further animal experiments.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30934052</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>07</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J Antimicrob Chemother</ISOAbbreviation></Journal><ArticleTitle>In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales.</ArticleTitle><Pagination><MedlinePgn>1921-1927</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkz102</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To evaluate the in vitro interactions of isavuconazole with immune suppressors (tacrolimus, cyclosporin A or sirolimus) against 30 Mucorales isolates belonging to the most common species responsible for mucormycosis in humans (Rhizopus arrhizus, Rhizopus delemar, Rhizopus microsporus, Lichtheimia corymbifera, Lichtheimia ramosa, Mucor circinelloides and Rhizomucor pusillus).</AbstractText><AbstractText Label="METHODS">In vitro interaction was evaluated by a microdilution chequerboard technique.</AbstractText><AbstractText Label="RESULTS">Combination of isavuconazole with tacrolimus, cyclosporin A or sirolimus, was synergistic for 50%, 46% and 7% of the isolates, respectively. Antagonistic interaction was observed for 4% of the isolates for the combination with cyclosporin A (one R. arrhizus isolate) and for 32% of the isolates for the combination with sirolimus (six R. arrhizus isolates and three R. pusillus isolates).</AbstractText><AbstractText Label="CONCLUSIONS">These in vitro data show that calcineurin inhibitors are more likely than inhibitors of the mTOR pathway to enhance the activity of isavuconazole against Mucorales. These in vitro results warrant further animal experiments.</AbstractText><CopyrightInformation>© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, Marburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Petra V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felske-Zech</LastName><ForeName>Heike</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, University Hospital Gießen, Gießen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dannaoui</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Université Paris Descartes, Faculté de Médecine, AP-HP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dynamyc Research Group (EA 7380), Paris Est Créteil University, Créteil, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014230">Triazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>60UTO373KE</RegistryNumber><NameOfSubstance UI="C508735">isavuconazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>83HN0GTJ6D</RegistryNumber><NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>WM0HAQ4WNM</RegistryNumber><NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009090" MajorTopicYN="N">Mucorales</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009091" MajorTopicYN="N">Mucormycosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>02</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>02</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30934052</ArticleId><ArticleId IdType="pii">5424934</ArticleId><ArticleId IdType="doi">10.1093/jac/dkz102</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>France</li></country><region><li>District de Giessen</li><li>Hesse (Land)</li><li>Île-de-France</li></region><settlement><li>Créteil</li><li>Marbourg</li><li>Paris</li></settlement><orgName><li>Université Paris-Descartes</li></orgName></list><tree><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Schwarz, Patrick" sort="Schwarz, Patrick" uniqKey="Schwarz P" first="Patrick" last="Schwarz">Patrick Schwarz</name></region><name sortKey="Felske Zech, Heike" sort="Felske Zech, Heike" uniqKey="Felske Zech H" first="Heike" last="Felske-Zech">Heike Felske-Zech</name><name sortKey="Schwarz, Patrick" sort="Schwarz, Patrick" uniqKey="Schwarz P" first="Patrick" last="Schwarz">Patrick Schwarz</name><name sortKey="Schwarz, Petra V" sort="Schwarz, Petra V" uniqKey="Schwarz P" first="Petra V" last="Schwarz">Petra V. Schwarz</name></country><country name="France"><region name="Île-de-France"><name sortKey="Dannaoui, Eric" sort="Dannaoui, Eric" uniqKey="Dannaoui E" first="Eric" last="Dannaoui">Eric Dannaoui</name></region><name sortKey="Dannaoui, Eric" sort="Dannaoui, Eric" uniqKey="Dannaoui E" first="Eric" last="Dannaoui">Eric Dannaoui</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000322 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000322 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30934052
|texte= In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30934052" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |